Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Other Income (Expense) : HK$-1,518 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Other Income (Expense)?

Shenzhen Hepalink Pharmaceutical Group Co's other income expense for the Shenzhen Hepalink Pharmaceutical Group Co's pretax income for the three months ended in Mar. 2024 was HK$-12 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,518 Mil.

Shenzhen Hepalink Pharmaceutical Group Co Other Income (Expense) Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Other Income (Expense) Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

799.64

521.52

-709.03

-100.07

-1,497.55

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Income (Expense)	Get a 7-Day Free Trial															12.13	-82.87	-180.56	-1,242.23	-12.06

Shenzhen Hepalink Pharmaceutical Group Co Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,518 Mil.

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Other Income (Expense)

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines